Lactogen Pro 1 Easy To 'Digest' For Babies? FSSAI Pulls Up Nestlé India For Scientific Proof
Nestle India is in focus.
· NDTV Profit
FSSAI has sought scientific evidence from Nestlé India for digestion and immunity claims on infant formula products, while Zydus Wellness faces scrutiny over Complan's growth, memory and immunity-related advertisements.
The analysis
Against that, the stock is -1.5% on the day at ₹1,223.90, and has returned -15.7% over three months. It sits 20% below its 52-week high. The fmcg sector has moved -6.4% over the same period, so Nestle India is running 9.3 points behind its peers.
For Nestle India, the question is how much of this is already reflected in the price and how much re-rates the fmcg peer set alongside it.
Market context
- The company directly in focus is NESTLEIND.
- Sector exposure: FMCG.
In this story
Related coverage
FSSAI issues notices to Nestlé India, Zydus Wellness over product claims
Taking Stock: Market fails to hold on to day#39;s gains, ends marginally higher
How Bajaj Consumer Care is defying an FMCG slowdown
Hindustan Unilever Q4 Preview: Price cuts, slow demand, regional competition to hurt topline
India-UK trade pact: Pernod, Diageo Scotch imports under tax scanner, says report